Ser486

Site Information
PRNysVGsRPLKPLs SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3175774

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 )
Disease tissue studied:	leukemia ( 6 ) , chronic myelogenous leukemia ( 6 ) , lung cancer ( 2 , 3 ) , non-small cell lung cancer ( 2 , 3 ) , non-small cell lung adenocarcinoma ( 2 , 3 )
Relevant cell line - cell type - tissue:	Calu-3 (pulmonary) ( 3 ) , HeLa (cervical) ( 1 , 4 ) , Jurkat (T lymphocyte) ( 5 ) , K562 (erythroid) ( 6 ) , NCI-H2073 (pulmonary) ( 2 )

References
1	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
2	Rikova K (2011) CST Curation Set: 11015; Year: 2011; Biosample/Treatment: cell line, NCI-H2073/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
3	Rikova K (2011) CST Curation Set: 11005; Year: 2011; Biosample/Treatment: cell line, Calu-3/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
4	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
5	Possemato A (2010) CST Curation Set: 9628; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
6	Stokes M (2008) CST Curation Set: 4394; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info